Evidence map›Paper›PMID 32581042›Full record

ArticleJournal for immunotherapy of cancer2020

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.

Andressa S Laino, David Woods, Melinda Vassallo, Xiaozhong Qian, Hao Tang, Megan Wind-Rotolo, Jeffrey Weber

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 6 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 6 syntheses or guidelines pooled it, 241 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Andressa S Laino *Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
David Woods *Department of Medicine, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-6328-8107
Melinda VassalloPerlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
Xiaozhong QianBristol-Myers Squibb, Princeton, New Jersey, USA.
Hao TangBristol-Myers Squibb, Princeton, New Jersey, USA.
Megan Wind-RotoloBristol-Myers Squibb, Princeton, New Jersey, USA.
Jeffrey WeberPerlmutter Cancer Center, NYU Langone Health, New York, New York, USA Jeffrey.Weber@nyulangone.org.
Bristol-Myers Squibb (United States) · USNYU Langone Health · USUniversity of Colorado Anschutz Medical Campus · US

Funding

Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic MelanomaR01CA175732 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WEBER, JEFFREY S · 2013 to 2017
$1.7M
Elucidating the Contextual Roles of IL-10 in Patient Response to Cancer ImmunotherapyR00CA230201 · NCI · UNIVERSITY OF COLORADO DENVER · PI WOODS, DAVID MICHAEL · 2020 to 2022
$709k
Elucidating the Contextual Roles of IL-10 in Patient Response to Cancer ImmunotherapyK99CA230201 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WOODS, DAVID MICHAEL · 2018 to 2019
$274k
NCI NIH HHS K99 CA230201NCI NIH HHS R00 CA230201NCI NIH HHS R01 CA175732
6 · The paper itself

Abstract

backgroundInflammatory mediators, including acute phase reactants and cytokines, have been reported to be associated with clinical efficacy in patients with melanoma and other cancers receiving immune checkpoint inhibitors (ICI). Analyses of patient sera from three large phase II/III randomized ICI trials, one of which included a chemotherapy arm, were performed to assess whether baseline levels of C-reactive protein (CRP), interleukin-6 (IL-6) or neutrophil/lymphocyte (N/L) ratios were prognostic or predictive. PATIENTS AND

methodsBaseline and on-treatment sera were analyzed by multiplex protein assays from immunotherapy-naïve patients with metastatic melanoma randomized 1:1 on the Checkmate-064 phase II trial of sequential administration of nivolumab followed by ipilimumab or the reverse sequence. Baseline sera, and peripheral blood mononuclear cells using automated cell counting, were analyzed from treatment-naïve patients who were BRAF wild-type and randomly allocated 1:1 to receive nivolumab or dacarbazine on the phase III Checkmate-066 trial, and from treatment-naïve patients allocated 1:1:1 to receive nivolumab, ipilimumab or both ipilimumab and nivolumab on the phase III Checkmate-067 trial.

resultsHigher baseline levels of IL-6 and the N/L ratio, and to a lesser degree, CRP were associated with shorter survival in patients receiving ICI or chemotherapy. Increased on-treatment levels of IL-6 in patients on the Checkmate-064 study were also associated with shorter survival. IL-6 levels from patients on Checkmate-064, Checkmate-066 and Checkmate-067 were highly correlated with levels of CRP and the N/L ratio.

conclusionIL-6, CRP and the N/L ratio are prognostic factors with higher levels associated with shorter overall survival in patients with metastatic melanoma receiving ICI or chemotherapy in large randomized trials. In a multi-variable analysis of the randomized phase III Checkmate-067 study, IL-6 was a significant prognostic factor for survival.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicC-Reactive ProteinFemaleHumansImmune Checkpoint InhibitorsInterleukin-6Kaplan-Meier EstimateMaleMelanomaMiddle AgedPrognosisProgression-Free SurvivalBiomarkers, TumorC-Reactive ProteinIL6 protein, humanImmune Checkpoint InhibitorsInterleukin-6biomarkers, tumorcytokinesimmunotherapy

Identifiers

PMID32581042
PMCPMC7312339
OpenAlexW3038009775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.